收藏切换
Research status and trends of clinical trials for new drug registration in China
收藏切换
PDF
Xiao-han WANG, Zhu-xing YAO, Wen-dong LIU, Xian SU, Yang-ping HU, Hai-xue WANG
Chinese Journal of Clinical Pharmacology | 2026, 42(2) : 274 - 278
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2026, 42(2): 274-278
Review
Research status and trends of clinical trials for new drug registration in China
Full
Xiao-han WANG, Zhu-xing YAO, Wen-dong LIU, Xian SU, Yang-ping HU, Hai-xue WANG
Affiliations
  • Center for Drug Evaluation, National Medical Products Administration, Beijing 102600, China
Published: 2026-01-28 doi: 10.13699/j.cnki.1001-6821.2026.02.020
Outline
收藏切换
Objective

To analyze the developmental status and core characteristics of new drug registration clinical trials in China, and to forecast future trends, thereby providing references for the research and development (R&D) layout of the pharmaceutical industry and the optimization of relevant policies.

Methods

Based on public data from the Annual Drug Evaluation Report and the Annual Report on the Progress of Clinical Trials for New Drug Registration in China published by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) from 2020 to 2024, a comprehensive analysis was conducted on the growth in the number of clinical trials, drug types, distribution of indications, implementation efficiency, and progress in key areas.

Results

In 2024, the total number of registered clinical trials reached 4 900, a record high. The proportion of Phase Ⅱ and Phase Ⅲ trials increased steadily, indicating continuous optimization of R&D efficiency. Clinical trials for chemical drugs and biological products were concentrated in the anti-tumor field, while trials for traditional Chinese medicine focused primarily on respiratory and digestive system diseases. Trials in key areas such as cell and gene therapy, drugs for rare diseases, and pediatric medications showed significant growth.

Conclusion

New drug clinical trials in China are demonstrating trends towards greater efficiency, innovation, and internationalization. Future efforts should focus on policy guidance and technological innovation to further optimize resource allocation, overcome homogeneous competition, and promote the high-quality development of the pharmaceutical industry.

new drug  /  registered clinical trial  /  antitumor drug  /  cell and gene therapy  /  clinical research and development efficiency
Xiao-han WANG, Zhu-xing YAO, Wen-dong LIU, Xian SU, Yang-ping HU, Hai-xue WANG. Research status and trends of clinical trials for new drug registration in China[J]. Chinese Journal of Clinical Pharmacology, 2026 , 42 (2) : 274 -278 . DOI: 10.13699/j.cnki.1001-6821.2026.02.020
Year 2026 volume 42 Issue 2
PDF
203
31
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2026.02.020
  • Receive Date:2025-12-08
  • Online Date:2026-08-06
  • Published:2026-01-28
Article Data
Affiliations
History
  • Received:2025-12-08
Affiliations
    Center for Drug Evaluation, National Medical Products Administration, Beijing 102600, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2026.02.020
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT